RETRACTED: Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study
- 1 October 2017
- journal article
- retracted article
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 5 (10) , 785-794
Abstract
No abstract availableKeywords
Funding Information
- Actelion Pharmaceuticals
This publication has 29 references indexed in Scilit:
- Macitentan and Morbidity and Mortality in Pulmonary Arterial HypertensionNew England Journal of Medicine, 2013
- Slow Receptor Dissociation Kinetics Differentiate Macitentan from Other Endothelin Receptor Antagonists in Pulmonary Arterial Smooth Muscle CellsPLOS ONE, 2012
- Evaluation of Patients with Chronic Thromboembolic Pulmonary Hypertension for Pulmonary EndarterectomyPulmonary Circulation, 2012
- Chronic Thromboembolic Pulmonary Hypertension (CTEPH)Circulation, 2011
- Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: Results from an international prospective registryThe Journal of Thoracic and Cardiovascular Surgery, 2011
- Pulmonary Hypertensive Medical Therapy in Chronic Thromboembolic Pulmonary Hypertension Before Pulmonary ThromboendarterectomyCirculation, 2009
- Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary HypertensionJACC, 2008
- Long-Term Recovery of Exercise Ability After Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary HypertensionThe Annals of Thoracic Surgery, 2006
- Inhaled Iloprost for Severe Pulmonary HypertensionNew England Journal of Medicine, 2002
- Pulmonary Vascular Lesions Occurring in Patients With Chronic Major Vessel Thromboembolic Pulmonary HypertensionChest, 1993